debra

KidneyCAN Legislative Patient Advocate

[KidneyCAN @kidneycan]

KidneyCAN is excited to share that we've made more room for you at #KCRS26!

In-person registration is available by request. Come join the world's leading #kidneycancer researchers as we connect and collaborate!

Can't get to Boston in July? We've saved you a free, virtual seat.

Register: https://t.co/btv2A7XXTS

[KidneyCAN @kidneycan]

Hey #kidneycancer researchers, got funding? Here's an option!

Named in honor of #immunotherapy pioneer Dr. Steven A. Rosenberg, this award recognizes promising early career scientists whose work is helping move cancer immunotherapy forward.

The 2026 Steven A. Rosenberg Scholars Award provides $150,000 in research funding to support innovative translational research.

Deadline: June 12, 2026
Submit a nomination: https://t.co/deHbvK9xnx

#AcceleratingCures

[KidneyCAN @kidneycan]

This Memorial Day, we pause to remember and honor the brave men and women who gave their lives in service to our country.

We are grateful for their sacrifice and extend our appreciation to all who have served, as well as the families who carry their legacy forward.

[KidneyCAN @kidneycan]

Early career investigators are helping shape the future of cancer immunotherapy research. SITC’s 2026 Steven A. Rosenberg Scholars Award recognizes outstanding scientists working to advance translational immuno-oncology research and address critical challenges in the field.

💰 $150,000 research award
🗓 Nominations due: June 12, 2026

Nominate here: https://t.co/deHbvK9xnx

#AcceleratingCures

[Katy Beckermann @katy_beckermann]

Non-ccRCC is not ccRCC with a different histology. WGS on 164 pRCC and ChRCC tumors maps three genomically distinct diseases, with direct implications for how we treat them.

📉 49% of ChRCC showed HLA LOH-based immune escape vs 4% of pRCC
🎯 63% of pRCC MET-amplified, potentially eligible for targeted therapy
🔬 TERT promoter: recurrent noncoding driver in pRCC (11/103 tumors)

Why this matters for practice: 💡 Supports genomic biomarker selection over histology alone for non-ccRCC trial design.

How are you approaching WGS in metastatic non-ccRCC? 🔬
https://t.co/z5R6Kl8ifU

#KidneyCancer #RCC #GUOnc

[Katy Beckermann @katy_beckermann]

We talk about bladder cancer often as a disease common in older men. This data says we need to update that mental model.

🔺 299K+ patients. Incidence rising fastest in <50.
🔺 Women now 38.9% of young-onset cases vs 18.9% historically.

This isn't a blip. It's a trend. And if we're not screening for it, we're diagnosing it late.

Why this matters in clinic: 💡 A young woman with hematuria isn't just a UTI until proven otherwise.

#BladderCancer #GUOncology

[KidneyCAN @kidneycan]

Getting a second opinion is a common step after a #KidneyCancer diagnosis. It can provide additional perspective, confirm a treatment plan, or introduce new options, helping you feel more confident in your care decisions.

Learn more: https://t.co/ptiOBSfmRF

#AcceleratingCures

[KidneyCAN @kidneycan]

Sometimes the most helpful step is simply talking to someone who understands. First Steps is a space to connect with others navigating a recent #KidneyCancer diagnosis.

Join us: https://t.co/rjWF420WTv

#AcceleratingCures

[KidneyCAN @kidneycan]

Navigating treatment side effects is a critical part of living with #KidneyCancer.

In a recent episode of Hot Topics in Kidney Health from the National Kidney Foundation, KidneyCAN patient advocate Andrew Allers share insights on managing side effects, recognizing warning signs, and making informed decisions about care.

Listen here! https://t.co/kuyXAG13Ul

#AcceleratingCures

[KidneyCAN @kidneycan]

#KCRS26 is built for meaningful scientific exchanges. We keep it deliberately focused, in one room with the world's leading kidney cancer researchers.

Present your work to a global audience of researchers, clinicians, and industry leaders committed to advancing #KidneyCancer research.

Apply by May 4: https://t.co/xUznBdxYU3

#AcceleratingCures

[KidneyCAN @kidneycan]

A #KidneyCancer diagnosis can feel overwhelming—but you don’t have to navigate it alone.

Join First Steps, a free virtual community social for newly diagnosed patients and caregivers. Connect, ask questions, and hear from others who understand.

🗓 May 13 | ⏰ 7:00–8:00 PM ET

Register here: https://t.co/T14Fh9EHGB

#AcceleratingCures

[KidneyCAN @kidneycan]

Advocacy is most powerful when people feel prepared, supported, and heard. At KidneyCAN, advocates are equipped with the tools and training to share their stories and speak directly to lawmakers about the importance of #KidneyCancer research funding.

Follow along with our advocacy efforts: https://t.co/va8umtnT5c

#AcceleratingCures

[KidneyCAN @kidneycan]

Support looks different for every family. Join us on April 21st to learn strategies, hear expert guidance, and connect with others navigating parenting and grandparenting alongside #KidneyCancer.

Register: https://t.co/RnTryeeJRJ

#AcceleratingCures

[KidneyCAN @kidneycan]

How do you start that conversation?

Join our upcoming Town Hall to hear how patients and caregivers navigated these first conversations with their children and families.

Register: https://t.co/RnTryeeJRJ

#AcceleratingCures

[KidneyCAN @kidneycan]

Planning for Medicare? This webinar can help!

Triage Cancer’s Medicare Made Simple session breaks down coverage options, enrollment timelines, and how to avoid common and costly mistakes.

🗓 April 22
⏰ 10am PT / 12pm CT / 1pm ET

Register now: https://t.co/BHLVsuZoI0

#AcceleratingCures

[KidneyCAN @kidneycan]

#ByTheNumbers: Spring Advocacy Days

Last month, advocates from across the country came together to meet with lawmakers and push for sustained #KidneyCancer research funding. Every meeting, every conversation, and every story shared helps move progress forward. Advocacy works, and this community continues to lead the way.

#AcceleratingCures #RestoreTheResearch

[KidneyCAN @kidneycan]

This month, KidneyCAN advocates came together in Washington, D.C. to make #KidneyCancer research a priority. Patients, caregivers, clinicians, and researchers met with lawmakers to push for sustained federal investment in the research that drives new treatments and saves lives.

Advocacy works—and this community continues to lead the way.

#RestoreTheResearch #AcceleratingCures

[KidneyCAN @kidneycan]

Today we want to recognize Lisa Lindsey, a dedicated KidneyCAN advocate whose voice and spirit have touched so many in the kidney cancer community.

Lisa has spent years lifting others up: sending paintings to fellow patients to bring moments of light during difficult days, organizing kidney cancer awareness events, and sharing her story to help others feel less alone. A nurse by training, she has always found ways to care for others, even organizing knitting and crochet projects to support families in her hospital’s NICU.

During our Faces of Kidney Cancer campaign, Lisa chose not only to share her own story, but to highlight the nurses who cared for her, submitting photos with them to honor their role in her journey. That’s who Lisa is: someone who always made sure others were seen, appreciated, and supported.

One of the quotes she shared with us captures her outlook perfectly:

“I won’t allow cancer to win. I will be traveling too fast… enjoying each moment of the beautiful life I have been given.”
— Lisa Lindsey

We are grateful for Lisa, her advocacy, and the joy she has brought to so many people in this community.

[KidneyCAN @kidneycan]

#ReedOn3!

The McLaughlin family has launched an incredible grassroots fundraiser to support #KidneyCancer research. Inspired by Reed McLaughlin, a devoted father, husband, coach, and loyal supporter of everyone around him, the Reed on 3 campaign is bringing people together to raise awareness and funds for kidney cancer.

Their goal is $50,000, and they’re already more than $22,000 of the way there!

Help them reach their goal: https://t.co/Rr72UQVE8s

#AcceleratingCures

[KidneyCAN @kidneycan]

Today, on #InternationalWomensDay, we recognize the women affected by #KidneyCancer, as patients, caregivers, researchers, and advocates.

While kidney cancer is more common in men, thousands of women are diagnosed each year, and outcomes can vary based on stage, access to care, and participation in clinical research. Women remain underrepresented in some areas of research, making awareness and inclusion especially important.

#AcceleratingCures #KidneyCancerAwarenessMonth